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Purpose: Patients with non-small cell lung cancer (NSCLC) and simultaneously 
having brain metastases at the initial diagnosis, presenting symptoms related brain 
metastasis, survived shorter duration and showed poor quality of life. We analyzed 
our experiences on surgical treatment of brain metastasis in patients with NSCLC. 
Materials and Methods: We performed a single-center, retrospective review of 
36 patients with NSCLC and synchronous brain metastases between April 2006 
and December 2011. Patients were categorized according to the presence of neuro-
logical symptoms and having a brain surgery. As a result, 14 patients did not show 
neurological symptoms and 22 patients presented neurological symptoms. Symp-
tomatic 22 patients were divided into two groups according to undergoing brain 
surgery (neurosurgery group; n=11, non-neurosurgery group; n=11). We analyzed 
overall surgery (OS), intracranial progression-free survival (PFS), and quality of 
life. Results: Survival analysis showed there was no difference between patients 
with neurosurgery (OS, 12.1 months) and non-neurosurgery (OS, 10.2 months; 
p=0.550). Likewise for intracranial PFS, there was no significant difference be-
tween patients with neurosurgery (PFS, 6.3 months) and non-neurosurgery (PFS, 
5.3 months; p=0.666). Reliable neurological one month follow up by the Medical 
Research Council neurological function evaluation scale were performed in symp-
tomatic 22 patients. The scale improved in eight (73%) patients in the neurosur-
gery group, but only in three (27%) patients in the non-neurosurgery group 
(p=0.0495). Conclusion: Patients with NSCLC and synchronous brain metasta-
ses, presenting neurological symptoms showed no survival benefit from neurosur-
gical resection, although quality of life was improved due to early control of neu-
rological symptoms.
Key Words:   Non-small cell lung cancer, brain metastasis, neurosurgery, quality 
of life, treatment outcome
INTRODUCTION
Brain metastases (BMs) are found in approximately 20‒40% of all patients with 
non-small cell lung cancer (NSCLC), especially in adenocarcinoma.1 The overall 
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tive survival prediction in patients with BM from various 
primary malignancies. This model has three classes based 
on age at diagnosis, presence or absence of extracranial me-
tastases, KPS, and primary tumor status. A higher RPA 
class represents a worse prognosis. This study was ap-
proved by the Institutional Review Board of Gangnam Sev-
erance Hospital, Yonsei University College of Medicine 
(IRB No: 3-2012-0179), and the necessity for written in-
formed consent was waived since this was a retrospective 
study and patients were anonymous.
Radiologic parameters of brain metastasis
Reviewed radiologic parameters of the brain metastases in-
cluded number, size, location, and functional grade.7 In ad-
dition, radiologic findings such as edema, hemorrhage, and 
necrosis were included. BM size was defined as the maxi-
mal orthogonal diameter based on T1-weighted gadolini-
um-enhanced magnetic resonance imaging (MRI). 
Treatment options for brain metastasis
Therapeutic approaches to brain metastases included sur-
gery, whole brain radiotherapy (WBRT), stereotactic ra-
diosurgery (SRS), and chemotherapy. Many patients were 
treated with combinations of these modalities. Treatment 
decisions took into account several parameters such as age, 
neurologic symptoms, functional status, and intracranial 
lesions. The decision as to whether intracranial lesions 
were surgically resected were based on neurologic symp-
toms and signs of intracranial hypertension unresponsive 
to adequate medical therapy (e.g., intravenous corticoste-
roid and/or mannitol), insufferable headaches, progressive 
motor weakness, gait disturbance, or dysarthria. Surgical 
indications were based on lesion-related relevant symp-
toms and radiologic brain imaging showing accessible lo-
cation and a mass effect due to edema unresponsive to 
medical therapy. 
Patients with an asymptomatic brain lesion or patients 
with symptoms showing poor performance status were rec-
ommended to undergo WBRT alone without surgery. In 
these patients, WBRT was delivered with 37.50 gray in 15 
fractions by two lateral beams of photons of 6 megavolts or 
30.00 gray in 10 fractions in patients with poor general 
health status and estimated survival less than 3 months. 
Once patients received surgery or radiotherapy, systemic 
platinum-based chemotherapy was started. Initially, two cy-
cles of systemic chemotherapy were administered. Follow-
ing response assessment after the first two cycles of chemo-
survival (OS) of these patients is generally poor, ranging 
from 3 to 6 months.2 Neurologically symptomatic patients 
have significantly shorter survival times than asymptomatic 
patients, as the median survival times have been estimated 
to be 4 and 7.5 months, respectively.3 
The optimal treatment for patients with neurologically 
symptomatic, synchronous (simultaneously having brain 
metastasis at the initial diagnosis), and multiple or solitary 
brain metastasis from NSCLC still remains controversial. 
Surgical resection of these metastatic lesions is considered 
in only 25% of patients.4 Recently, surgery for stage IV 
NSCLC (involving an isolated brain or adrenal gland me-
tastasis) has been recommended as a treatment option if 
mediastinal lymph nodes are not involved.5 Brain metasta-
tectomy is generally considered for patients who demon-
strate good performance status and have a solitary, accessi-
ble, symptomatic brain metastasis with significant mass 
effect, and in addition, for those who need a histologic di-
agnosis and for those in whom previous radiation therapy 
has failed.4 Recently, due to advances in surgical tech-
niques, more lesions are now accessible, and surgical com-
plications and post-surgical morbidity have been reduced 
compared to the situation in the past.  
In this study, we retrospectively evaluated OS, intracranial 
progression-free survival (PFS), prognostic factors, and op-
timal treatment for brain metastasis in patients with neuro-
logically symptomatic, synchronous brain metastasis from 
NSCLC and compared patients in the neurosurgery group, 
the non-neurosurgery group, and the asymptomatic group.
MATERIALS AND METHODS
Patient characteristics
Medical records at Gangnam Severance Hospital from 
April 2006 through December 2011 were reviewed to iden-
tify patients who presented with synchronous brain metas-
tasis from NSCLC. In all patients, brain metastases were 
confirmed at the initial diagnosis of the primary lung can-
cer. The subjects of this study were 36 patients with or 
without neurological symptoms. Symptomatic patients 
were divided into two groups according to the surgery per-
formed for the brain metastases. The medical records of 
each subject were examined for gender, age, smoking histo-
ry, initial symptoms, pathology, Karnofsky Performance 
Status (KPS), and Recursive Partitioning Analysis (RPA) 
class.6 RPA is the most commonly used model for prospec-
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RESULTS
 
Demographic characteristics
A total of 36 patients were histologically confirmed as 
NSCLC and radiologically diagnosed as having brain me-
tastasis between April 2006 and December 2011. Fourteen 
patients did not present with neurological symptoms and 22 
patients presented with neurological symptoms at admis-
sion. Of the neurologically symptomatic 22 patients, 11 pa-
tients were treated with neurosurgical treatment and 11 pa-
tients were not treated with neurosurgery. Non-neurosurgery 
group was treated with WBRT or palliative therapy. Table 1 
shows the characteristics of 22 patients with neurologically 
symptomatic, synchronous brain metastasis from NSCLC. 
Between the neurosurgery and non-neurosurgery groups, 
there were no significant differences in any characteristics 
evaluated. Current or past smoking status, performance sta-
tus, prognostic factors, and neurological scale by MRC neu-
rological function evaluation at initial diagnosis showed no 
differences between the two treatment groups. 
Pathology, number of brain metastasis and treatment 
modalities
Table 2 shows the pathologic diagnosis and the number of 
brain metastases and treatment modalities which the symp-
tomatic 22 patients and asymptomatic 14 patients under-
went. In the neurosurgery group, six patients (55%) showed 
multiple synchronous metastases and five patients (45%) 
showed solitary metastasis. In the non-neurosurgery group, 
7 patients (64%) showed multiple metastasis and 4 (36%) 
patients showed single metastasis. These patients were clas-
sified for treatment modality. Of the 11 patients in the neu-
rosurgery group, 10 patients were followed by WBRT or 
SRS and AS patients received WBRT or SRS only.
In all patients in the neurosurgery group, the one lesion 
that was the largest, symptomatic, and surgically accessible 
was resected. The resected lesions ranged in size from 1.9 
to 5.6 cm (median 3.4 cm). The characteristics of multiple 
metastatic lesions, each patient’s performance scale, and 
OS are summarized in Table 3.
Treatment outcomes
We analyzed OS and PFS, after excluding 4 patients (3 pa-
tients treated with neurosurgery group; 1 patient treated 
without neurosurgery) harboring sensitive EGFR mutations 
and treated with EGFR-TKIs following neurosurgery or ra-
therapy and in the absence of progression either at the 
primary lung tumor or BM, chemotherapy was indicated. 
Four patients harboring sensitive epidermal growth factor 
receptor (EGFR) mutations continuously received EGFR-
tyrosine kinase inhibitors (EGFR-TKIs) following surgery 
or radiotherapy. Palliative treatment only (steroids and anti-
convulsants) was administered to patients with poor perfor-
mance status or high comorbidity, or to patients who did 
not agree to undertake invasive treatment. 
Follow-up schedules
Follow-up for primary lung cancer was performed with 
computed tomography, generally every 2 months. Follow-
up for brain metastases was conducted by MRI, usually ev-
ery two months. Treatment response in patients with BM 
was evaluated according to the Response Evaluation Crite-
ria in Solid Tumors (RECIST) criteria after every two cy-
cles in chemotherapy or radiotherapy.
The tumor response in the BM was evaluated by enhanced 
brain MRI and neurological findings. Neurological status 
was assessed using the Medical Research Council (MRC) 
neurological function scale at 1 month after intracranial treat-
ment.8 If there were measurable lesions, the tumors were 
evaluated based on the RECIST version 1.1 criteria. If there 
were no measurable lesions, the tumor response was classi-
fied as partial response, stable disease, or progressive dis-
ease based on the enhanced brain MRI findings and neuro-
logical findings. Intracranial progression after neurosurgical 
resection or radiotherapy was defined as either progressive 
enlargement of the enhancing lesion or no change in tumor 
size but persistent, symptomatic edema. 
Statistical analysis
Data were analyzed with SAS 9.2 version (SAS Institute 
Inc., Cary, NC, USA). OS was defined as the time elapsed 
from the starting date of treatment of the brain metastasis or 
pulmonary lesions to the date of death or the date of last fol-
low-up. Intracranial PFS was defined as the time from the 
date of the start of treatment to the date of documented dis-
ease progression or death from any cause. Risk factors af-
fecting the survival rate were found using Fisher’s exact test 
and log-rank test, thus multiple survival analyses with ad-
justed and associated risk factors were performed using 
Cox’s proportional hazard regression model. Median time to 
intracranial progression and OS were analyzed by the Ka-
plan-Meier estimator. Significance was set at a p-value of 
<0.05. All tests were two-sided.
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Table 1. Demographic and Clinical Characteristics of 22 Patients with Neurologically Symptomatic, Synchronous Brain Me-
tastasis from NSCLC
Characteristics NSR (n=11) Non-NSR (n=11) p value
Sex 1.000
    Male 9 10
Age 0.553
    Median (range) 65.6 (50‒81) 61.9 (40‒76)
    <65 5   6
    ≥65 6   5
Smoking history 1.000
    Never 8   8
    Former or current 3   3
Pathology 1.000
    Adenocarcinoma 8   8
    Squamous cell carcinoma 1   1
    NSCLC-not otherwise specified 2   2
Number of brain metastases (%) 0.475
    Single 5 (45) 4 (36)
    Multiple 6 (55) 7 (64)
KPS score 0.635
    ≥70 8   7
    <70 3   4
RPA class 0.325
    Class I 3   0
    Class II 6   8
    Class III 2   3
MRC scale* 0.716
    1 0   0
    2 or 3 5   6
    4 or 5 6   5
NSCLC, non-small cell lung cancer; NSR, neurosurgical resection; KPS, Karnofsky Performance Status; RPA, recursive partitioning analysis. 
1. No neurological deficit. 2. Some deficit but adequate function for useful work. 3. Deficits causing moderate functional impairment (e.g., moderate 
dysphasia, moderate paresis, or visual disturbance such as field defect). 4. Deficit causing major functional impairment (e.g., inability to use limb, gross 
speech impairment, or visual disturbances). 5. Inability to make conscious responses.
*Medical Research Council (MRC) neurological function scale.  
Table 2. Treatment Modality in 36 Patients with Synchronous Brain Metastasis Originating from NSCLC
NSR (n=11) Non-NSR (n=11) AS (n=14)
Brain metastasis
    NSR   1 0   0
    NSR+WBRT (or SRS) 10 0   0
    WBRT   0 9 13
    Palliative only   0 2   1
Primary cancer
    Chemotherapy (TKIs)* 9 (3) 10 (1) 9 (1)
    Chemotherapy+radiation   1 0   3
    Palliative only   1 1   2
NSR, neurosurgical resection; AS, asymptomatic; WBRT, whole brain radiotherapy; SRS, stereotactic radiosurgery; TKIs, tyrosine kinase inhibitors; NSCLC, 
non-small cell lung cancer.
*Patients received epidermal growth factor receptor (EGFR)-TKI treatment after the identification of EGFR mutation on the tissue from brain metastasis le-
sion.
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for each group. There were no significant differences be-
tween the groups in terms of these characteristics. Current-
ly, two patients are alive without recurrence after treatment 
of intracranial metastasis. These patients are from the non-
neurosurgery.
Neurological function score
Reliable neurological 1-month follow-up using the MRC 
neurological function evaluation scale was available for 22 
symptomatic patients. The MRC scale improved in 8 (73%) 
neurosurgery patients and did not change in 3 (27%) neuro-
surgery patients, whereas it improved in 3 (27%) non-neu-
rosurgery patients, worsened in one (9%) non-neurosurgery 
diotherapy, because such patients are usually responsive to 
EGFR-TKIs and show favorable prognosis.
There was no difference in survival between 8 patients 
with neurosurgery (OS, 12.1 months) and 10 patients with 
non-neurosurgery (OS, 10.2 months; p=0.550). Likewise for 
intracranial PFS, there was no significant difference between 
the neurosurgery group (6.3 months) and the non-neurosur-
gery group (5.3 months; p=0.666) (Fig. 1). Additionally, 
there was no difference in OS (p=0.363) and intracranial PFS 
between the symptomatic group (neurosurgery group plus 
non-neurosurgery group) and the asymptomatic group (n= 
14, p=0.083) (Table 4). Table 4 also shows the response after 
BM treatment (p=0.669) and the cause of death (p=0.773) 
Table 3. Features of Six Patients with Neurologically Symptomatic, Synchronous and Multiple Brain Metastasis Who Re-
ceived Neurosurgery
 1 2 3 4 5 6
Brain image
    No. of metastasis 5 2 2 3 10 3
    No. of resection 1 1 1 1 1 1
    Size (cm) 3.1 5.6 1.9    2.5 2.7 4.6
    Site Parietal Cerebellum Cortex Cerebellum Parietal Cerebellum
    Edema + + + + + +
    Hemorrhage + - - - - +
    Necrosis + - - - - -
    Mass effect + + + + + +
PS
    KPS score ≥70 ≥70 ≥70 <70 <70 ≥70
    RPA class II II II III III I
OS (month) 13 4 23 4 13 16
EGFR 
    Mutation analysis - - Mutant Mutant Wild Mutatn
    Selected regimen - - Erlotinib Gefitinib - Gefitinib
PS, performance status; KPS, Karnofsky Performance Status; RPA, recursive partitioning analysis status; OS, overall survival; EGFR, epidermal growth fac-
tor receptor. 
Fig. 1. Kaplan-Meier estimate curves of OS (A) and intracranial PFS (B) for NSR and non-NSR group patients. OS, overall survival; PFS, progression free sur-
vival; NSR, neurosurgical resection.
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occur in 30‒50% of patients with NSCLC, and confers a poor 
prognosis and a negative impact on quality of life (QOL) dur-
ing the course of their disease.10-12 Patients with NSCLC 
and synchronous brain metastasis on initial diagnosis, who 
presented with neurological deficits, had a short median 
survival and lower QOL.3 Studies have been performed on 
the effect of neurosurgery for brain metastasis in the pa-
tients with neurological symptoms on diagnosis; however, 
their results were limited to patients with a solitary metasta-
sis.13-16 We performed early surgical treatment of brain metas-
tasis (including multiple metastases) in patients with lowered 
performance status (i.e., KPS <70 or RPA class II or III) (Ta-
ble 1). Early surgical treatment controlled the progression of 
brain metastasis and improved neurologic symptoms, and 
was followed by better performance status that enabled sys-
temic chemotherapy (Fig. 2).
patient, and did not change in 7 (64%) non-neurosurgery 
patients. 
The cumulative MRC neurological function scale scores 
of the initial symptom for the two groups were 26 for the 
neurosurgery group and 27 for the non-neurosurgery group 
(i.e., there was no difference in scores). However, the cumu-
lative scale scores at 1 month after BM treatment were 16 
for the neurosurgery group and 24 for the non-neurosurgery 
group, indicating a better functional outcome after neurosur-
gery (p=0.0495) (Fig. 2).
DISCUSSION
Brain metastases are identified in 7.4‒10.0% of patients with 
NSCLC upon initial diagnosis.9 Moreover, brain metastases 
Table 4. Clinical Outcome of 32 Patients with Synchronous Brain Metastasis from NSCLC
Clinical outcome
Symptomatic Asymptomatic 
(n=14) p value*Total (n=18) NSR (n=8) Non-NSR (n=10) p value
Median OS (month)   9.5 12.1 10.2 0.550 13.1 0.363
Intracranial PFS (month)   4.5   6.3   5.3 0.666   8.4 0.083
BM response (No.) 0.827 0.669
    PR   9   5   4   5
    SD   3   1   2   4
    PD   6   2   4   5
Cause of death (No.) 0.775 0.773
    Intracranial   4   2   2   3
    Extracranial   3   2   1   3
    Both   9   4   5   8
    Total 16   8   8 14
OS, overall survival; PR, partial response; SD, stable disease; PD, progression of disease; BM, brain metastasis; NSCLC, non-small cell lung cancer; PFS, 
progression-free survival; NSR, neurosurgical resection.
*p value between symptomatic vs. asymptomatic patients.
Fig. 2. Cumulative change of MRC neurological function scale at 1-month follow-up after therapy for brain metastasis. (A) NSR group (n=11). (B) Non-NSR 
group (n=11). p=0.0495. *Medical Research Council (MRC) neurological function scale. NSR, neurosurgical resection.
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ths.24 For patients with favorable prognostic features [good 
performance status, younger age (<65 years), well-con-
trolled status of the primary lung cancer, and absence of ex-
tra-cranial metastasis6,25-27], treatment with SRS and WBRT 
could prolong OS to 11.6 months.28 Using RPA as a prog-
nostic factor, meta-analyses by the Radiation Therapy On-
cology Group trials on brain metastasis treated with SRS 
showed that the median survival of the best prognosis group 
(RPA class I: age <65 years, KPS ≥70, and a controlled sys-
temic disease) was 7.1 months. The expected survival of 
the worst prognosis group (RPA class III: KPS <70) was 
only 2.3 months.6 Until now, treatment for brain metastases 
includes surgery, SRS, WBRT, or a combination of these 
modalities, and has achieved median survival ranging from 
6.5 to 11.0 months.28-32 
In our present study, neurosurgery group showed no sig-
nificant differences in survival rate (OS, 12.1 months) com-
pared with non-neurosurgery group (OS, 10.2 months) (Ta-
ble 4), and showed a favoring trend with 1.9 months, even 
though patients with a poor prognostic factor (RPA class II 
or III) were included, compared with the previous data.28,32 A 
previous study showed a prolonged survival only in patients 
in the AS group compared to symptomatic synchronous pa-
tients.3 Our study showed a similar survival rate between pa-
tients in the AS group (OS, 13.1 months) and patients in the 
neurosurgery group (OS, 12.1 months), and failed to show 
any statistical significance between the neurosurgery group 
(OS, 12.1 months) and the non-neurosurgery group (OS, 
10.2 months) (Table 4).
In patients with a symptomatic, synchronous brain metas-
tasis from NSCLC, the brain lesion mostly has life-threaten-
ing mass effects and causes focal neurological deficits that 
may considerably decrease the functional grade. Thus, ear-
ly surgery can immediately provide symptom relief and im-
prove QOL in the patients. 
There are several limitations in the present study. First, it 
was a retrospective study, the study population was small, 
and the research was carried out in a single institution, con-
sequently, it is difficult to generalize this result to other set-
tings. Second, we compared OS between three treatment 
groups without considering the control of primary lung can-
cer. We could not exclude systemic chemotherapeutic effect 
for primary lung cancer, and brain metastasis is usually con-
sidered most crucial factor in mortality. A large-scale pro-
spective randomized study is needed for generalization of 
this result.
In conclusion, patients with synchronous brain metastasis, 
Recently, surgical intervention has demonstrated increased 
survival rates and decreased complications of post-opera-
tion as positive benefits; therefore, resection of a single brain 
metastasis has become the standard treatment option in pa-
tients with good functional status and controlled extra-cra-
nial disease.15,16 Advances in surgical techniques have led to 
lower rates of morbidity and in-hospital mortality, with esti-
mates as low as 1.8% in high-volume centers.17 However, in 
the case of multiple brain metastases, surgery is usually lim-
ited to patients with a dominant, symptomatic, or life-threat-
ening lesion and to those who require a tissue diagnosis be-
fore proceeding with therapy. However, two recent single-
center retrospective studies have suggested that patients with 
good prognostic features and two to three metastases may 
gain same survival benefit from surgery as patients with one 
metastasis, if the dominant lesion is resected.18,19 Despite 
these benefits of surgical resection, surgical candidates can-
not clearly be defined. There is especially insufficient evi-
dence to make a recommendation for patients with poor 
performance status, advanced systemic disease, or multiple 
brain metastases.
In our present study, surgery was performed for accessi-
ble brain metastasis causing a mass effects, peri-tumoral ce-
rebral edema, and insufferable neurological deficits even if 
patients had poor performance status or multiple brain me-
tastases. There were no complications in 11 patients from 
the neurosurgery group. Neurological symptomatic com-
plaints of neurosurgery group patients were relieved signifi-
cantly compared to those of the non-neurosurgery group 1 
month after surgery, as indicated by the MRC neurological 
function evaluation scale (Fig. 2). Furthermore, it is impor-
tant to confirm tissue pathology before proceeding with 
therapy because it is recommended as an option for the first 
line treatment of NSCLC patients who have a brain metas-
tasis and harbor an EGFR mutation with EGFR-TKIs.20,21 
Moreover, discordance in the EGFR mutation status be-
tween the primary and metastatic brain lesions has been re-
cently reported in several studies and the discordance rate 
was reported to reach 27‒28%.22,23 In our study, early EG-
FR-TKI treatment was conducted in three of nine patients 
receiving systemic chemotherapy, after identification of the 
EGFR mutation on the metastatic brain tissue (Table 2).
Diverse clinical studies have been carried out to provide a 
guideline for the optimal treatment of patients with a symp-
tomatic, synchronous brain metastasis from NSCLC. The 
median survival of patients treated with only supportive care 
(such as corticosteroids) has been estimated to be 1‒2 mon-
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